Advertisement

Topics

Ironwood secures FDA fast track designation for heart drug praliciguat

07:02 EDT 14 Sep 2018 | Pharmaceutical Business Review

Praliciguat is an investigational, orally administered soluble guanylate cyclase (sGC) stimulator currently in Phase II clinical trials. Ironwood chief development officer and global development senior vice president Christopher

The post Ironwood secures FDA fast track designation for heart drug praliciguat appeared first on Pharma Business review.

Original Article: Ironwood secures FDA fast track designation for heart drug praliciguat

NEXT ARTICLE

More From BioPortfolio on "Ironwood secures FDA fast track designation for heart drug praliciguat"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...